|
Name |
Rubiginosin B
|
| Molecular Formula | C21H22O8 | |
| IUPAC Name* |
[(6R,7R)-6-hydroxy-3-[(E)-3-hydroxyprop-1-enyl]-7-methyl-8-oxo-5,6-dihydro-1H-isochromen-7-yl] 2,4-dihydroxy-6-methylbenzoate
|
|
| SMILES |
CC1=CC(=CC(=C1C(=O)O[C@@]2([C@@H](CC3=C(C2=O)COC(=C3)/C=C/CO)O)C)O)O
|
|
| InChI |
InChI=1S/C21H22O8/c1-11-6-13(23)9-16(24)18(11)20(27)29-21(2)17(25)8-12-7-14(4-3-5-22)28-10-15(12)19(21)26/h3-4,6-7,9,17,22-25H,5,8,10H2,1-2H3/b4-3+/t17-,21-/m1/s1
|
|
| InChIKey |
ZRJGOGLZGFEQJT-RIEYKTBPSA-N
|
|
| Synonyms |
Rubiginosin B; Rubinosin A; CHEMBL4080026; ZRJGOGLZGFEQJT-RIEYKTBPSA-; J3.616.327E; [(6R,7R)-6-hydroxy-3-[(E)-3-hydroxyprop-1-enyl]-7-methyl-8-oxo-5,6-dihydro-1H-isochromen-7-yl] 2,4-dihydroxy-6-methylbenzoate
|
|
| CAS | NA | |
| PubChem CID | 11269635 | |
| ChEMBL ID | CHEMBL4080026 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 402.4 | ALogp: | 1.4 |
| HBD: | 4 | HBA: | 8 |
| Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 134.0 | Aromatic Rings: | 3 |
| Heavy Atoms: | 29 | QED Weighted: | 0.562 |
| Caco-2 Permeability: | -5.398 | MDCK Permeability: | 0.00001270 |
| Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.826 |
| Human Intestinal Absorption (HIA): | 0.284 | 20% Bioavailability (F20%): | 0.956 |
| 30% Bioavailability (F30%): | 0.91 |
| Blood-Brain-Barrier Penetration (BBB): | 0.078 | Plasma Protein Binding (PPB): | 83.73% |
| Volume Distribution (VD): | 0.841 | Fu: | 14.67% |
| CYP1A2-inhibitor: | 0.916 | CYP1A2-substrate: | 0.252 |
| CYP2C19-inhibitor: | 0.108 | CYP2C19-substrate: | 0.065 |
| CYP2C9-inhibitor: | 0.372 | CYP2C9-substrate: | 0.604 |
| CYP2D6-inhibitor: | 0.562 | CYP2D6-substrate: | 0.138 |
| CYP3A4-inhibitor: | 0.813 | CYP3A4-substrate: | 0.191 |
| Clearance (CL): | 7.207 | Half-life (T1/2): | 0.884 |
| hERG Blockers: | 0.021 | Human Hepatotoxicity (H-HT): | 0.746 |
| Drug-inuced Liver Injury (DILI): | 0.962 | AMES Toxicity: | 0.37 |
| Rat Oral Acute Toxicity: | 0.717 | Maximum Recommended Daily Dose: | 0.977 |
| Skin Sensitization: | 0.939 | Carcinogencity: | 0.553 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.391 |
| Respiratory Toxicity: | 0.348 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003304 | ![]() |
0.818 | D07MGA | ![]() |
0.273 | ||
| ENC002211 | ![]() |
0.775 | D04AIT | ![]() |
0.234 | ||
| ENC002726 | ![]() |
0.649 | D0K8KX | ![]() |
0.230 | ||
| ENC003837 | ![]() |
0.633 | D08NQZ | ![]() |
0.226 | ||
| ENC002132 | ![]() |
0.627 | D0J2NK | ![]() |
0.222 | ||
| ENC002725 | ![]() |
0.596 | D02GAC | ![]() |
0.221 | ||
| ENC003615 | ![]() |
0.583 | D0AZ8C | ![]() |
0.221 | ||
| ENC003448 | ![]() |
0.477 | D08LTU | ![]() |
0.221 | ||
| ENC002798 | ![]() |
0.472 | D07VLY | ![]() |
0.217 | ||
| ENC003640 | ![]() |
0.455 | D0C9XJ | ![]() |
0.217 | ||